

What is Cobenfy?

Also known as KarXT or xanomeline-trospium

This page gives information on Cobenfy, a groundbreaking new drug to treat schizophrenia. It has been licensed for use in the United States, but not yet in England. This information is for people who are 18 or over and affected by mental illness in England.

What is Cobenfy?

Cobenfy is the first new medication for [schizophrenia](#) in many decades.¹

Medications for schizophrenia are known as [antipsychotics](#).

It is an exciting development as compared to existing antipsychotics:

- it can treat more symptoms, and
- it has fewer side effects.

The United States Food and Drug Administration (FDA) have approved Cobenfy, for the treatment of schizophrenia in the United States.²

But the drug is not yet licenced for use in England, and we are not sure when it will be. But we wanted to keep you up to date with this new development.

For more information see below - **When will Cobenfy be available for use in England?**

Cobenfy was formerly known as KarXT or xanomeline-trospium.

You can find out more about how it was developed in [this article](#) by the **Wellcome Trust**. They helped fund research into Cobenfy.

How does Cobenfy work?³

Current antipsychotics work by blocking some of the dopamine receptors in the brain. This can lead to side effects. These side effects can:

- have a bad effect on the quality of people's lives, or
- mean some people stop taking the medication, causing them to experience symptoms again. This is known as 'relapse'.

Current antipsychotics do not help treat symptoms for about 3 or 4 in 10 people who try them.⁴

Cobenfy does not work by blocking some of the dopamine receptors in the brain.

Cobenfy works in a new way. It stimulates muscarinic receptors.⁵ This is complicated. But you can find out more [here](#) and from this [explainer video](#).

The video is by John H. Krystal, Chair of the department of psychiatry at the Yale School of Medicine in the United States.

Cobenfy combines 2 different drugs into one treatment:⁶

- **Xanomeline** – this reduces schizophrenia symptoms.
- **Trospium chloride** – this helps counter side effects caused by xanomeline.

Why is Cobenfy important?

Current antipsychotics:

- **can treat** what are known as '**positive symptoms**', like hallucinations and delusions, but
- **do not treat** what are known as '**negative symptoms**', like lack of motivation or social withdrawal, and
- usually have **troubling side-effects**.

See our page on [Antipsychotics](#) for more information.

Trials in the US show patients who took **Cobenfy showed improvements in:**⁷

- **both negative and positive symptoms**, and
- **cognitive symptoms**, like memory or concentration problems, and
- **side effects** that current antipsychotics cause, such as sleepiness, weight gain and unusual body movements.

It is hoped that if people are experiencing fewer side effects, they will be more likely to take the medication.⁸

Because of the way it works, Cobenfy may improve symptoms for those who do not respond to existing antipsychotics.⁹

Some elements of the drug to do with cognitive improvements still need to be researched further.¹⁰

Does Cobenfy have side effects or any warnings?¹¹

Like a lot of medications, Cobenfy can have potential side effects.

The most common side effects are nausea, indigestion, constipation, vomiting, hypertension, abdominal pain, diarrhoea, increased heartbeat, dizziness and gastroesophageal reflux disease.¹²

It can also cause other issues such as urinary retention, increased heart rate, decreased gastric movement or swelling beneath the skin of the face and lips.¹³

So, some people:¹⁴

- may respond better than others to the medication, and
- will not be able to take it at all.

You can read more in this **US Food and Drug administration news release**.

When will Cobenfy be available for use in England?

Cobenfy has been licensed for use in United States. But it will not be widely available there for around a year from September 2024.¹⁵

Before Cobenfy is available to be widely prescribed in England, it must go through a number of steps, including:¹⁶

- Lab testing and clinical trials,
- Approval by [The Medicines and Healthcare products Regulatory Agency \(MHRA\)](#), and
- Approval by [The National Institute for Health and Care Excellence \(NICE\)](#)

So, it is unclear when Cobenfy will be available to be widely prescribed in England.

These steps are needed to make sure the medication is safe and is affordable.

There are likely to be different ongoing trials of the medication. One study will look at Cobenfy's use as an add-on treatment for those who do not respond well to existing antipsychotics.¹⁷

The **University of Oxford** says it will be doing the first UK trial of Cobenfy in 2025.¹⁸

We will update this page when we have more information about when Cobenfy might be available in England.

What can I do if I am having issues with my antipsychotics?

You might be having issues with your antipsychotics or their side effects. Speak to your psychiatrist as soon as you can.

You might have issues seeing your psychiatrist. Speak to someone at your mental health team, your GP, or a pharmacist.

It is important that you do not stop taking your medication without getting advice first.

You can get more advice and information in our page on [Medication - choice and managing problems](#)

Did this help?

We would love to know if this information helped you or if you found any issues with this factsheet. You can email us at feedback@rethink.org

References

- ¹ BMJ. *Schizophrenia: US approves first new treatment in decades*. <https://www.bmj.com/content/386/bmj.q2133.full> (Accessed 8 October 2024)
- ² Psychiatric times. *FDA Approves Cobenfy, A First In-Class Agent for Schizophrenia*. See para 1 <https://www.psychiatrictimes.com/view/fda-approves-cobenfy-for-schizophrenia> (accessed 9 October 2024)
- ³ Wellcome. *A new approach for treating schizophrenia* <https://wellcome.org/news/new-treatment-for-schizophrenia-Cobenfy> (accessed 8 October 2024)
- ⁴ Psychiatric times. *FDA Approves Cobenfy, A First In-Class Agent for Schizophrenia*. See para 5, last line <https://www.psychiatrictimes.com/view/fda-approves-cobenfy-for-schizophrenia> (accessed 9 October 2024)
- ⁵ Psychiatric Times. *The FDA Approval of Cobenfy: A Historic Moment in Schizophrenia*. See Video, 0.59 seconds in. <https://www.psychiatrictimes.com/view/the-fda-approval-of-cobenfy-a-historic-moment-in-schizophrenia> (accessed 8 October 2024)
- ⁶ Hasan A, Abid M (9 October 2024) Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. *Cureus* 16(10): e71131. doi:10.7759/cureus.71131. See 'Editorial' para 3 <https://www.cureus.com/articles/306991-cobenfy-xanomeline-trospium-chloride-a-new-frontier-in-schizophrenia-management#!> (accessed 9 October 2024)
- ⁷ Wellcome. *A new approach for treating schizophrenia* <https://wellcome.org/news/new-treatment-for-schizophrenia-Cobenfy> (accessed 8 October 2024)
- ⁸ Psychiatric Times. *The FDA Approval of Cobenfy: A Historic Moment in Schizophrenia*. See Video, 3.15 seconds in. <https://www.psychiatrictimes.com/view/the-fda-approval-of-cobenfy-a-historic-moment-in-schizophrenia> (accessed 8 October 2024)
- ⁹ Psychiatric times. *FDA Approves Cobenfy, A First In-Class Agent for Schizophrenia*. See para 5, last line <https://www.psychiatrictimes.com/view/fda-approves-cobenfy-for-schizophrenia> (accessed 9 October 2024)
- ¹⁰ Psychiatric Times. *The FDA Approval of Cobenfy: A Historic Moment in Schizophrenia*. See Video, 6.10 seconds in. <https://www.psychiatrictimes.com/view/the-fda-approval-of-cobenfy-a-historic-moment-in-schizophrenia> (accessed 8 October 2024)
- ¹¹ US Food and Drug administration. *FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia*. See para 6,7 & 8 <https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia> (accessed 11 October 2024)
- ¹² US Food and Drug administration. *FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia*. See para 6,7 & 8 <https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia> (accessed 11 October 2024)

-
- ¹³ US Food and Drug administration. *FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia*. See para 6,7 & 8 <https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia> (accessed 11 October 2024)
- ¹⁴ Science Media Centre. *Expert reaction to news that the FDA has approved the drug Cobenfy (KarXT) for schizophrenia*. See 'Prof David Curtis, Honorary Professor, UCL, said:' Paras 2 & 3 <https://www.sciencemediacentre.org/expert-reaction-to-news-that-the-fda-has-approved-the-drug-cobenfy-karxt-for-schizophrenia/> (accessed 11 October 2024)
- ¹⁵ Psychiatric Times. *The FDA Approval of Cobenfy: A Historic Moment in Schizophrenia*. See Video, 3.56 seconds in. <https://www.psychiatrictimes.com/view/the-fda-approval-of-cobenfy-a-historic-moment-in-schizophrenia> (accessed 8 October 2024)
- ¹⁶ Debra. *How drugs are approved* <https://www.debra.org.uk/drug-approval-process> (accessed 9 October 2024)
- ¹⁷ Discovery development. *Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years*. See future directions paragraph 2 <https://oxfordglobal.com/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years> (accessed 11 October 2024)
- ¹⁸ European pharmaceutical review. *First-in-class therapy approved for schizophrenia* <https://www.europeanpharmaceuticalreview.com/news/234077/first-in-class-therapy-approved-for-schizophrenia/> (accessed 9 October 2024)

© Rethink Mental Illness 2024

Last updated: October 2024. Next update: October 2025, subject to any changes.

Version: 1

This factsheet is available in large print.

Rethink Mental Illness Advice Service

Phone 0808 801 0525

**Monday to Friday, 9:30am to 4pm
(excluding bank holidays)**

Email

Did this help?

We'd love to know if this information helped you

Drop us a line at: feedback@rethink.org

or write to us at Rethink Mental Illness:

RAIS

PO Box 18252

Solihull

B91 9BA

or call us on 0808 801 0525

We're open 9:30am to 4pm

Monday to Friday (excluding bank holidays)



Equality, rights, fair treatment, and the maximum quality of life for all those severely affected by mental illness.

For further information on Rethink Mental Illness Phone 0121 522 7007
Email info@rethink.org



rethink.org

Need more help?

Go to rethink.org for information on symptoms, treatments, money and benefits and your rights.

Don't have access to the web?

Call us on 0121 522 7007. We are open Monday to Friday, 9am to 5pm, and we will send you the information you need in the post.

Need to talk to an adviser?

If you need practical advice, call us on: 0808 801 0525 between 9:30am to 4pm, Monday to Friday. Our specialist advisers can help you with queries like how to apply for benefits, get access to care or make a complaint.

Can you help us to keep going?

We can only help people because of donations from people like you. If you can donate please go to rethink.org/donate or call 0121 522 7007 to make a gift. We are very grateful for all our donors' generous support.



Registered with
FUNDRAISING
REGULATOR



CYBER
ESSENTIALS



INVESTORS IN PEOPLE
We invest in people Silver

